Combination treatment for amyotrophic lateral sclerosis (ALS)
US10220077B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2013 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Nov 14, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y104/01003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.